Oral EPI-7386 in Patients With Metastatic Castration-Resistant Prostate Cancer

  • STATUS
    Recruiting
  • participants needed
    40
  • sponsor
    ESSA Pharmaceuticals
Send
Updated on 19 February 2024
See if I qualify
metastasis
progressive disease
bone scan
metastatic castration-resistant prostate cancer
soft tissue disease
bone lesion
castration-resistant prostate cancer
diphosphonates

Summary

This is a phase I, clinical research study of EPI-7386, an investigational drug being studied as a treatment for patients with prostate cancer. All patients in the study will receive EPI-7386.

Since this is the first study of EPI-7386 in humans, there is no information about how it affects people or what dose should be used. Therefore, the main purpose of this study is to assess the safety (side effects) of EPI-7386 and to find a dose that can be given without unacceptable side effects.

There are other important things that will be evaluated during the study:

  • How the amount of EPI-7386 in the blood changes over time.
  • The effect of EPI-7386 on prostate cancer.
  • The effect of EPI-7386 on certain substances in the body.
  • The possibility that EPI-7386 can interact with other drugs.

Details
Condition Malignant neoplasm of prostate, Prostatic disorder
Age 18-100 years
Treatment EPI-7386
Clinical Study IdentifierNCT04421222
SponsorESSA Pharmaceuticals
Last Modified on19 February 2024

Eligibility

 Yes No Not Sure

Inclusion Criteria

Male 18 years of age or older
Histologically, pathologically, or cytologically confirmed prostate cancer without small cell features
Evidence of castration-resistant prostate cancer (CRPC)
Presence of metastatic disease at study entry documented by 1 or more bone lesions on bone scan or by soft tissue disease observed by CT/MRI
No further treatment options available known to confer clinical benefit in this disease setting from the perspective of the treating physician
Evidence of progressive disease defined as 1 or more Prostate Cancer Working Group 3 (PCWG3) criteria
The patient must have recovered from toxicities related to any prior treatments
Castrate at screening
Patients receiving bisphosphonates or other approved bone-targeting therapy must be on a stable dose for at least 4 weeks prior to the start of study drug
Demonstrate adequate organ function
Eastern Cooperative Oncology Group (ECOG) performance status score of 0 to 1

Exclusion Criteria

Biologic anti-cancer therapy or a cytotoxic chemotherapy within 4 weeks prior to the start of study drug
Use of hormonal agents with anti-tumor activity against prostate cancer within 4 weeks prior to the start of study drug
Intervention with any chemotherapy, investigational agents, or other anti-cancer drugs within 14 days or 5 half-lives, whichever is longer, of the first dose of study drug
Use of radium-223 dichloride or other radioligand/radiopharmaceutical within 28 days prior to the start of study drug
Received limited-field palliative bone radiotherapy >5 fractions and/or any radiotherapy within 2 weeks prior to the start of study drug
Received a blood transfusion within 28 days of screening
Known intra-cerebral disease or brain metastasis unless adequately treated and stable for the last 4 weeks before enrollment
Spinal cord compression
Diagnosis of another invasive malignancy within the previous 3 years other than curatively treated non-melanomatous skin cancer or superficial urothelial carcinoma
Gastrointestinal disorder affecting absorption
Significant cardiovascular disease
Concurrent disease or any clinically significant abnormality
Use of compounds known to be strong inducers and strong inhibitors of CYP3A and CYP2C8 within 14 days of the first dose of study drug
Use of narrow therapeutic index sensitive CYP2C8 or sensitive substrates for CYP3A and CYP2B6
Clear my responses
Read more

How to participate?

Step 1 Connect with a study center
What happens next?
  • You can expect the study team to contact you via email or phone in the next few days.
  • Sign up as volunteer  to help accelerate the development of new treatments and to get notified about similar trials.

You are contacting

Investigator Avatar

Primary Contact

site

Additional screening procedures may be conducted by the study team before you can be confirmed eligible to participate.

Learn more

If you are confirmed eligible after full screening, you will be required to understand and sign the informed consent if you decide to enroll in the study. Once enrolled you may be asked to make scheduled visits over a period of time.

Learn more

Complete your scheduled study participation activities and then you are done. You may receive summary of study results if provided by the sponsor.

Learn more

Similar trials to consider

Browse trials for

metastasis
progressive disease
bone scan
metastatic castration-resistant prostate cancer
soft tissue disease
bone lesion
castration-resistant prostate cancer
diphosphonates

Not finding what you're looking for?

Every year hundreds of thousands of volunteers step forward to participate in research. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.

Sign up as volunteer

user name
Edit Delete

Added by • 

 • 

Private

Edit Delete

Reply by • • Private
Edit Delete

Lorem ipsum dolor sit amet consectetur, adipisicing elit. Ipsa vel nobis alias. Quae eveniet velit voluptate quo doloribus maxime et dicta in sequi, corporis quod. Ea, dolor eius? Dolore, vel!

  The passcode will expire in None.

No annotations made yet

Add a private note
  • abc Select a piece of text from the left.
  • Add notes visible only to you.
  • Send it to people through a passcode protected link.
Add a private note
  • abc Select a piece of text.
  • Add notes visible only to you.
  • Send it to people through a passcode protected link.